NCT05869669
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
Sponsor
EIP Pharma
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, the aim of this study is to find out if you experience any improvement in your: Verbal learning, memory, and attention; Cognitive and functional performance.
This study is currently enrolling.